Literature DB >> 22527892

Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin.

Ludovico Abenavoli, Natasa Milic, Francesco Capasso.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22527892     DOI： 10.1007/s12020-012-9677-0

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  5 in total

1.  Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease.

Authors:  Ludovico Abenavoli
Journal:  Hepatol Res       Date:  2011-06-22       Impact factor: 4.288

2.  Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males.

Authors:  Rui Wang; Qiang Lu; Ji Feng; Fuzai Yin; Chunmei Qin; Bo Liu; Yali Liu; Xiaoli Liu
Journal:  Endocrine       Date:  2011-07-28       Impact factor: 3.633

Review 3.  Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.

Authors:  E Scorletti; P C Calder; C D Byrne
Journal:  Endocrine       Date:  2011-09-06       Impact factor: 3.633

Review 4.  Role of adipocytokines in predicting the development of diabetes and its late complications.

Authors:  Nese Ersoz Gulcelik; Aydan Usman; Alper Gürlek
Journal:  Endocrine       Date:  2009-09-25       Impact factor: 3.633

5.  Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice.

Authors:  Giovanni Li Volti; Salvatore Salomone; Valeria Sorrenti; Andrea Mangiameli; Vincenzo Urso; Ilias Siarkos; Fabio Galvano; Federico Salamone
Journal:  Cardiovasc Diabetol       Date:  2011-07-14       Impact factor: 9.951
  5 in total
  7 in total

Review 1.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

2.  Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.

Authors:  Jun Liang; Ying Liu; Jinguang Liu; Zhe Li; Qiangyuan Fan; Zifei Jiang; Fei Yan; Zhi Wang; Peiwen Huang; Nianping Feng
Journal:  J Nanobiotechnology       Date:  2018-09-04       Impact factor: 10.435

3.  Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study.

Authors:  Zhongni Liu; Hong Li; Yinghong Zheng; Ziyu Gao; Lin Cong; Liming Yang; Yong Zhou
Journal:  Sci Rep       Date:  2018-07-04       Impact factor: 4.379

4.  Therapeutic Effects of Milk Thistle (Silybum marianum L.) and Artichoke (Cynara scolymus L.) on Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Rats.

Authors:  Aida Doostkam; Mohammad Fathalipour; Mohammad Hossein Anbardar; Azar Purkhosrow; Hossein Mirkhani
Journal:  Can J Gastroenterol Hepatol       Date:  2022-02-11

5.  Antioxidant Effects and Phytochemical Properties of Seven Taiwanese Cirsium Species Extracts.

Authors:  Zi-Wei Zhao; Hung-Chi Chang; Hui Ching; Jin-Cherng Lien; Hui-Chi Huang; Chi-Rei Wu
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

6.  Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma.

Authors:  Eva-Maria Pferschy-Wenzig; Atanas G Atanasov; Clemens Malainer; Stefan M Noha; Olaf Kunert; Daniela Schuster; Elke H Heiss; Nicholas H Oberlies; Hildebert Wagner; Rudolf Bauer; Verena M Dirsch
Journal:  J Nat Prod       Date:  2014-03-05       Impact factor: 4.050

7.  Comparison of the Hepatoprotective Effects of Four Endemic Cirsium Species Extracts from Taiwan on CCl₄-Induced Acute Liver Damage in C57BL/6 Mice.

Authors:  Zi-Wei Zhao; Jen-Chih Chang; Li-Wei Lin; Fan-Hsuan Tsai; Hung-Chi Chang; Chi-Rei Wu
Journal:  Int J Mol Sci       Date:  2018-04-30       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.